Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles

• Published in: ACS biomaterials science & engineering Vol. 7; no. 3; pp. 1074 - 1087
• Main Authors: Norouzi, Parisa, Motasadizadeh, Hamidreza, Atyabi, Fatemeh, Dinarvand, Rassoul, Gholami, Mahdi, Farokhi, Mehdi, Shokrgozar, Mohammad Ali, Mottaghitalab, Fatemeh
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 08-03-2021
• Subjects: Animals; Controlled Release and Delivery Systems; Doxorubicin; Fibroins; Mice; Nanoparticles; Neoplasms; Polyethyleneimine; RNA, Small Interfering - genetics; Survivin - genetics; Tissue Distribution; nanoparticle; combination therapy; breast cancer; survivin siRNA; doxorubicin; silk fibroin
• ISSN: 2373-9878; 2373-9878
• DOI: 10.1021/acsbiomaterials.0c01511

Here, polyethylenimine (PEI) modified silk fibroin nanoparticles (SFNPs) were prepared for codelivery of doxorubicin (DOX) and survivin siRNA. The prepared NPs were characterized in terms of stability and structural, functional, and physicochemical properties. Moreover, the ability of the conjugate to escape from the endosome and cellular uptake were assessed. Afterward, the in vivo therapeutic efficacy was analyzed in the mice model. The siRNA loaded PEI-SFNPs showed acceptable size, zeta potential, and stability in serum. It also effectively induced apoptosis in the 4T1 mouse mammary tumor cell line. Cellular uptake and endosomal escape analyses confirmed that PEI-SFNPs containing siRNA could escape from the endosome and accumulate in the cytoplasm of 4T1 cells. Real time-PCR indicated the significant decrease in the expression of survivin mRNA in the 4T1 cell line 48 h postincubation with siRNA loaded PEI-SFNPs. In vivo biodistribution of PEI-SFNPs confirmed higher accumulation of SFNPs in the tumor site compared with other organs. The codelivery systems remarkably reduced the growth rate of breast tumor in the mice model without any obvious weight lost. Histopathological and tunnel staining exhibited more apoptotic tumor cells in the group containing both DOX and survivin siRNA. Tumorigenic breast tissue resected from the animals after treatment with siRNA also exhibited significant suppression of survivin gene. In conclusion, the prepared drug delivery system had an acceptable potential in tumor removal, apoptosis induction in cancer cells, and therapeutic efficacy. Thus, it would be a good candidate for breast cancer therapy.